STF-083010

别名: IRE1 Inhibitor I; STF-083010; STF 083010; STF083010 N-[(2-羟基-1-萘基)亚甲基]-2-噻吩磺酰胺
目录号: V1900 纯度: ≥98%
STF-083010(以前称为 IRE1 Inhibitor I)是一种新型、特异性的 IRE1α 核酸内切酶小分子抑制剂。
STF-083010 CAS号: 307543-71-1
产品类别: IRE1
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes
点击了解更多
  • 与全球5000+客户建立关系
  • 覆盖全球主要大学、医院、科研院所、生物/制药公司等
  • 产品被大量CNS顶刊文章引用
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

产品描述
STF-083010 (formerly IRE1 Inhibitor I) is a novel and specific small-molecule inhibitor of IRE1α endonuclease. In many solid tumors and hematologic malignancies, including multiple myeloma (MM), the adaptive Ire1-XBP1 pathway has been found to be activated. Following endoplasmic reticulum stress in both vitro and vivo, STF-083010 reduced Ire1 endonuclease activity without affecting its kinase activity. In models of human MM xenografts, STF-083010 treatment demonstrated significant antimyeloma activity. STF-083010, in contrast to other similarly isolated cell populations, was preferentially toxic to freshly isolated human CD138(+) MM cells. The discovery of this new Ire1 inhibitor lends credence to the idea that the Ire1-XBP1 axis represents a promising target for anticancer therapy, particularly in the context of MM. STF-083010 exhibits dose- and time-dependent cytostatic and cytotoxic activity in MM.1S, MM.1R, and RPMI 8226 MM cell lines. STF-083010 blocks IRE1α's endonuclease activity without affecting its kinase activity in the MiaPaCa2, Panc0403, and SU8686 cell lines. It also inhibits the splicing of XBP1. After three days of culture, STF-083010 shows a 70% growth inhibition in Eμ-TCL1 CLL cells. STF-083010 inhibits 20% of growth in MEC1 and MEC2 cells within 48 hours. WaC3 cells react to STF-083010 treatments by gradually slowing their growth.
生物活性&实验参考方法
靶点
Ire1
体外研究 (In Vitro)
STF-083010 exhibits dose- and time-dependent cytotoxic and cytostatic activity in MM.1S, MM.1R, and RPMI 8226 MM cell lines.[1] [2] STF-083010 blocks IRE1's endonuclease activity in MiaPaCa2, Panc0403, and SU8686 cell lines without affecting XBP1 splicing or its kinase activity.[1] After three days of culture, STF-083010 shows a growth inhibition of about 70% in STF-083010 exhibits dose- and time-dependent cytotoxic and cytostatic activity in MM.1S, MM.1R, and RPMI 8226 MM cell lines. [1] [2] STF-083010 blocks IRE1's endonuclease activity in MiaPaCa2, Panc0403, and SU8686 cell lines without affecting XBP1 splicing or its kinase activity. [1] After three days of culture, STF-083010 shows a growth inhibition of about 70% in E-TCL1 CLL cells. In 48 hours, STF-083010 inhibits 20% of growth in MEC1 and MEC2 cells. WaC3 cells respond to STF-083010 treatments by gradually slowing their growth. [3]-TCL1 CLL cells. In 48 hours, STF-083010 inhibits 20% of growth in MEC1 and MEC2 cells. WaC3 cells respond to STF-083010 treatments by gradually slowing their growth. [3]
体内研究 (In Vivo)
STF-083010 (i.p., 30 mg/kg) significantly slows the growth of the tumor in a human multiple myeloma (MM) xenograft model. [1]
酶活实验
The presence of 32P-γATP controls the activity of autophosphorylation. By adding radiolabeled HAC1 508-nt RNA substrate that has been in vitro synthesized using 32P-UTP, endonuclease activity is assessed. Radiolabeled HAC1 508 nt RNA, recombinant hIRE1 protein, and the appropriate buffers are all added to STF083010. Electrophoresis of polyacrylamide gels is used to measure kinase activity. 32P-γATP or 32P-UTP autoradiography is used to quantify the products of RNA scleavage.
细胞实验
The following day, drug treatment was begun after 3000 cells were seeded in 96-well plates over night. The stop solution (4 mM HCl, 0.1% Nondet P40 in isopropanol), which is added to dissolve the MTT, is then added to the cells after 48 hours of incubation. MTT is added to the cells and cultured for 4 hours at 37°C. With a reference wavelength of 630 nm, a spectrophotometer reads the plates at 590 nm absorbance. Utilizing GraphPad Prism, IC50 values are computed.
动物实验
Mice: The right and left hind footpads of each BALB/c nude mouse (male, 5 weeks old) are subcutaneously inoculated with 5×106 HCT116 p53+/+ or HCT116 p53-/- cells. After four days, DMSO or STF-083010 (40 mg/kg) is injected intraperitoneally every three days. Every five days, tumors are measured, and their volumes are calculated using the formula mm3=(length (mm))×(width (mm))2/2).
参考文献

[1]. Blood . 2011 Jan 27;117(4):1311-4.

[2]. Oncotarget . 2014 Jul 15;5(13):4881-94.

[3]. Blood . 2012 Aug 2;120(5):1027-38.

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C15H11NO3S2
分子量
317.38
精确质量
317.02
元素分析
C, 56.77; H, 3.49; N, 4.41; O, 15.12; S, 20.20
CAS号
307543-71-1
相关CAS号
307543-71-1
外观&性状
Solid powder
SMILES
C1=CC=C2C(=C1)C=CC(=C2/C=N/S(=O)(=O)C3=CC=CS3)O
InChi Key
TVIVJHZHPKNDAQ-MHWRWJLKSA-N
InChi Code
InChI=1S/C15H11NO3S2/c17-14-8-7-11-4-1-2-5-12(11)13(14)10-16-21(18,19)15-6-3-9-20-15/h1-10,17H/b16-10+
化学名
(NE)-N-[(2-hydroxynaphthalen-1-yl)methylidene]thiophene-2-sulfonamide
别名
IRE1 Inhibitor I; STF-083010; STF 083010; STF083010
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外)
DMSO: ~63 mg/mL (~198.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
溶解度 (体内)
Solubility in Formulation 1: ≥ 3.25 mg/mL (10.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: 2% DMSO+40%PEG 300+5% Tween80 +ddH2O: 2mg/mL

请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 3.1508 mL 15.7540 mL 31.5080 mL
5 mM 0.6302 mL 3.1508 mL 6.3016 mL
10 mM 0.3151 mL 1.5754 mL 3.1508 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

生物数据图片
  • STF-083010


    The IRE1α inhibitor (STF-083010) suppresses the growth in vitro and in vivo of p53-deficient human cancer cells. From: Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway.2015 Aug 21;6(24):19990-20001.

  • STF-083010


    Anti-proliferative activities of IRE1αinhibitors. From: Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.2014 Jul 15;5(13):4881-94.

  • STF-083010


    Effect of STF or HNA on expression of UPR target genes in pancreatic cancer cells. From: Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.2014 Jul 15;5(13):4881-94.

相关产品
联系我们